Effects of the MIND diet on cardiometabolic health and novel anthropometric measures in women with type 2 diabetes and insomnia: a randomized controlled trial Authors: Mona Golmohammadi, Vahideh Ebrahimzadeh Attari, Yahya Salimi, Lotfollah Saed, Seyed Mostafa Nachvak, Mehnoosh Samadi Published: 2025 ABSTRACT AbstractWomen with diabetes are at an elevated risk for cardiovascular disease (CVD), and insomnia exacerbates these risks, highlighting the urgent need for effective interventions that improve cardiometabolic health and reduce mortality in this population. This study aimed to evaluate the effects of the MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet on cardiometabolic health and novel anthropometric indices in 44 women, aged 30 to 65, with type 2 diabetes and insomnia. In this randomized controlled trial, participants were assigned to either the MIND low-calorie diet (MLCD) or a standard low-calorie diet (LCD) for 12 weeks. Outcomes assessed at baseline and after 12 weeks included lipid profiles, markers of glycemic control, blood pressure, and anthropometric measures. The results revealed that the MIND diet significantly improved fasting blood sugar (FBS) (-19.31, 95% CI: -38.43 to -0.19), total cholesterol (TC) (-24.49, 95% CI: -35.05 to -13.93), low-density lipoprotein cholesterol (LDL-c) (-20.31, 95% CI: -32.67 to -7.95), systolic blood pressure (SBP) (-7.75, 95% CI: -12.46 to -3.05), diastolic blood pressure (DBP) (-2.51, 95% CI: -4.28 to -0.73), waist circumference (WC) (-1.64, 95% CI: -2.71 to -0.57), waist-to-hip ratio (WHR) (-0.02, 95% CI: -0.04 to -0.002), waist-to-height ratio (WHtR) (-0.01, 95% CI: -0.02 to -0.004), and body roundness index (BRI) (-0.26, 95% CI: -0.45 to -0.07), compared to the control group (p < 0.05). These findings suggest that the MIND diet could be a feasible and beneficial dietary approach to improving cardiometabolic outcomes in women with type 2 diabetes and insomnia, although further research is needed to confirm these results. Trial registration Trial registration number: IRCT20181111041611N8 on 07/08/2023.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12937-025-01275-6.Keywords: MIND diet, Diabetes mellitus, Cardiometabolic risk factors, Anthropomeric, Obesity Introduction Diabetes mellitus (DM) is the most common chronic disease worldwide. The International Diabetes Federation predicts that diabetes will affect approximately 783 million people globally by 2045. DM significantly increases the risk of both microvascular and macrovascular complications, including cardiovascular diseases (CVDs), which are the primary cause of mortality and morbidity in people with diabetes [1, 2]. Cardiometabolic risk factors, including obesity and excessive body fat, dyslipidemia, hypertension, and insulin resistance, significantly influence the development and progression of CVDs. Regarding these risk factors are notably more prevalent in patients with DM [3], their effective management is crucial to prevent the onset and progression of CVDs in diabetic patients. Insomnia, characterized by difficulty in initiating sleep, maintaining sleep, or achieving restful sleep, is a common problem in people with diabetes [4]. Insomnia not only complicates the management of DM, but also increases the risk of CVD by 45% [5]. The MIND (Mediterranean-DASH Diet Intervention for Neurodegenerative Delay) diet was introduced in 2015 as a novel dietary approach that integrates elements of two established diets: the Mediterranean diet and the DASH (Dietary Approaches to Stop Hypertension) diet [6]. A prominent aspect of the MIND diet is its emphasis on consuming berries and green leafy vegetables, which are rich in phytochemicals and polyphenols [6–8]. The MIND dietary pattern also emphasizes the consumption of whole grains, vegetables, nuts, and legumes, which collectively increase dietary fiber intake, helping control blood sugar by reducing insulin resistance, delaying glucose absorption, and altering gut microbiota and circulating metabolites [9, 10]. Additionally, dietary polyphenols reduce insulin resistance primarily by improving insulin signaling through the IRS-1/PI3K/Akt pathway [11]. They protect pancreatic β-cells from oxidative stress, enhance insulin secretion via FFAR1 activation, and promote autophagy to prevent β-cell apoptosis [11]. Polyphenols also modulate ion channels (K⁺ and Ca²⁺ currents), further stimulating insulin release and improving glucose homeostasis [11]. The diet also limits refined carbohydrates, pastries and sweets, further improving metabolic profiles in people with diabetes [12]. In addition, green leafy vegetables and berries contribute to neuronal function and sleep regulation. Green leafy vegetables are abundant sources of magnesium, an essential mineral involved in neuronal function and sleep regulation [13], acting as a cofactor for N-acetyltransferase, the enzyme responsible for converting serotonin to melatonin [14]. Additionally, berries, rich in flavonoids and melatonin, play an important role in facilitating sleep onset through their calming effect on the nervous system [15]. Furthermore, chronic hyperglycemia in diabetes contributes to endothelial dysfunction, oxidative stress, and systemic inflammation, all of which aggravate existing cardiometabolic risk factors [3]. Moreover, the coexistence of chronic inflammation, dyslipidemia, and insulin resistance further contributes to hypertension and increases cardiovascular risk [3]. The MIND dietary pattern may thus promote cardiovascular health in this vulnerable population by mitigating oxidative stress and inflammation through its bioactive components [16, 17]. According to a recent study, adherence to the MIND diet was associated with significant changes in triglyceride (TG) levels, systolic and diastolic blood pressure, fasting blood sugar levels (FBS), and high density lipoprotein cholesterol (HDL-c) in adults [18]. In a cross-sectional study of 339 obese individuals, a significant positive association was found between following the MIND dietary pattern and insulin sensitivity. However, no significant associations were found for other cardiometabolic risk factors [19]. Moreover, in another study by Yau et al., 72 elderly participants with hypertension showed significant reductions in total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), and glucose after following the MIND diet for four weeks [20]. These inconsistencies in the literature may be explained by variations in participant characteristics, differences in adherence levels to the MIND dietary pattern, and heterogeneity in study design. Despite some promising findings regarding the health benefits of the MIND diet on cardiometabolic risk factors, the results are still inconsistent, and its effect on DM has not yet been assessed. Thus, the present study aimed to investigate the impact of the MIND dietary pattern on novel anthropometric parameters and cardiometabolic risk factors in women with diabetes and obesity who also experience insomnia. Materials and methods Participants and sample size An open-label RCT (randomized clinical trial) was conducted on 44 women with diabetes aged 30–65 years who were overweight or obese and suffered from insomnia in Sanandaj, Iran. The sample size was determined according to the article by Daneshzad et al. [21] using the Pittsburgh Sleep Quality Index (PSQI) variable with a type 1 error of 5% (α = 0.05) and a power of 95% (power = 95%). Consequently, 18 participants were assigned to each group. However, accounting for a predicted fall rate of 20%, the number of participants was increased to 22 in each group. Inclusion and exclusion criteria Inclusion criteria were 1) patients with type 2 DM, 2) aged 30–65 years, 3) having Insomnia [Insomnia Severity Index (ISI) score of more than 7], and 4) Body Mass Index (BMI) of 25 to 35 kg/m2. Exclusion criteria included pregnant and breastfeeding subjects, individuals using insulin, and patients with a history of specific medical conditions, including metabolic, endocrine, and psychiatric disorders. In addition, subjects with shift work or sleep apnea, subjects who had been on a weight-loss diet or taking supplements in the last three months, and subjects who consumed alcohol or tobacco were excluded from the study. Procedure Participants were randomly assigned in a 1:1 ratio to follow either a MIND low-calorie diet (MLCD) or a low-calorie diet (LCD) for 12 weeks, using block randomization and sealed opaque envelopes to ensure allocation concealment. The randomization process was conducted by a researcher who had no direct contact with the participants. Participants were regularly followed up during the 12-week intervention period. This was an open-label trial, meaning the participants and the nutritionists providing the dietary counseling were aware of the group assignments. However, to minimize detection bias, all outcome assessors (including those performing anthropometric measurements and the laboratory staff analyzing biochemical data) were kept blind to the participants’ group allocation. The primary outcome for this trial was the change in sleep quality, as assessed by the PSQI, the results of which are reported elsewhere [22]. The outcomes reported in the present article, including changes in cardiometabolic risk factors and novel anthropometric indices, were pre-specified secondary outcomes of the trial. Diets The intervention methodology was described in detail in the protocol article [23]. In summary, a low-calorie diet was implemented to achieve a weight loss of 250 to 500 gr per week in both the MLCD and LCD groups. The control group adhered to a low-calorie diet emphasizing healthy foods, and the intervention group adhered to the MIND dietary pattern consisting of six meals and snacks per day (Supplemental Table 1) [24]. To encourage dietary adherence, participants received phone calls weekly and met with a nutritionist every month. Participants could talk about their problems without time pressure, which increased their commitment to adhering to the prescribed diet. Dietary adherence was further monitored using a food record questionnaire, in which participants documented their dietary intake three times per month, including one weekend day and two weekdays. Participants were also encouraged to maintain their current level of physical activity throughout the intervention period. The MIND diet score The MIND diet score was calculated based on the dietary pattern originally developed by Morris et al. (2015) [24], excluding wine consumption due to cultural and religious restrictions. Dietary intake was recorded over three non-consecutive days (two weekdays and one weekend day) at both the beginning and end of the study. The score comprised 14 food components instead of 15, with higher scores indicating greater consumption of brain-healthy foods and lower consumption of unhealthy foods. The detailed method for calculating the scores was described in our previous article [23]. Adherence to the MIND dietary pattern was defined as achieving a score of 11 or higher [25]. Assessment of sleep quality The PSQI was used to assess sleep quality at the beginning and the end of the research period [26]. Measurement of novel anthropometric indices Anthropometric indices, including weight, height, waist circumference (WC), and hip circumference (HC) were measured with precise instruments. Weight and height were measured with a digital Seca scale and a Seca height measuring device, respectively. Waist and hip circumference were measured with a rigid tape measure at specific anatomical landmarks. Finally, BMI, waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR) were calculated using the appropriate formulas. The detailed measurement procedure was explained in our previous article [23]. Novel anthropometric indices, including body roundness index (BRI) [27], body adiposity index (BAI) [28], lipid accumulation product index (LAP) [29], visceral adiposity index (VAI) [30], cardiometabolic index (CMI) [31], and a body shape index (ABSI) [32] were calculated based on the formulas below: Assessment of cardiometabolic risk markers After a fasting period of 10 to 12 h, 12 cc of blood was collected from all participants at the beginning and end of the intervention. Serum levels of FBS, TC, HDL-c, and TG were determined by the calorimetric method (Pars Azmun; Iran), Hemoglobin A1C (HbA1C) by the immunoturbidimetric method (Pars Azmun; Iran), and insulin levels by the electrochemiluminescence immunoassay (ECLIA) method (Roche-Kit; Germany). To calculate insulin resistance, insulin sensitivity, and LDL-c, the following formulas were used [33–35]: Statistical analysis Statistical analysis was conducted with SPSS version 21.0, setting the significance level at p < 0.05. All analyses were performed according to the intention-to-treat (ITT) principle, including all 44 randomized participants. As there was 100% follow-up with no dropouts, the ITT population was identical to the per-protocol population. All data were presented as mean ± standard deviation. The normality of the variables was assessed using the Kolmogorov-Smirnov test. For normally distributed data, between-group comparisons were performed using the independent sample t-test, and within-group comparisons were conducted using the paired-sample t-test. In cases where the data were non-normally distributed, the non-parametric Mann-Whitney test was used for between-group comparisons, and the Wilcoxon signed-rank test was applied for within-group comparisons. Additionally, linear regression examined the relationship between independent and dependent variables. No subgroup analyses based on baseline characteristics (e.g., age or BMI) were performed for this report. Ethics approval This study received ethical approval from the Ethics Committee at Kermanshah University of Medical Sciences (IR.KUMS.REC.1402.170) and was included in the Iranian Registry of Clinical Trials (IRCT20181111041611N8) on 07/08/2023. Following the ethical principles outlined in the Declaration of Helsinki by the World Medical Association, participants received detailed information about the objectives and procedures of the study, after which they provided their consent by signing a formal agreement. Results Participant characteristics The study began in October 2023 and had a duration of six months. A total of 238 individuals were initially screened for eligibility, of whom 194 were excluded for various reasons. The remaining 44 participants were randomly allocated equally to the intervention and control groups (22 participants per group). All participants completed the 3-month intervention period without any adverse effects. As all participants in the intervention group achieved MIND diet scores above 11, none were excluded based on this criterion. No participants were lost to follow-up, and analyses were performed on all randomized participants. The participant flow diagram has been published previously and is therefore not included in this manuscript [22]. As indicated in Table 1, there were no statistically significant differences in baseline characteristics between the two groups. Additional baseline data have been reported in detail in our previous publication and showed no significant differences between groups (p >0.05) [22]. Table 1Baseline characteristics of study participantsVariablesMIND Diet (n = 22)Control Group (n = 22)P-valueAge; years55.36 (7.44)54.68 (7.68)0.766Energy (Kcal/d)1959.91 (363.25)1957.58 (494.66)0.986Carbohydrate (%kcal)57.57 (6.49)56.88 (4.66)0.685Protein (%kcal)15.41 (1.67)15.45 (2.05)0.949Fat (%kcal)29.68 (6.21)30.09 (3.04)0.783PSQI; score9.68 (3.68)11.14 (3.40)0.181ISI; score13.45 (4.08)14.36 (4.63)0.494DASS; score35.45 (27.22)41.27 (16.85)0.400Physical activity; n (%)*0.507 Low18 (81.8%)19 (86.4%) Moderate3 (13.6%)1 (4.5%) High1 (4.5%)2 (9.1%)Data are mean ± SD or n (%)DASS depression anxiety stress scales, ISI Insomnia Severity Index, PSQI pittsburgh sleep quality index*Physical activity was categorized into the following levels: low: <600 (MET/min/week),medium: 600–2999 (MET/min/week) and high: ≥3000 (MET/min/week) Baseline characteristics of study participants Data are mean ± SD or n (%) DASS depression anxiety stress scales, ISI Insomnia Severity Index, PSQI pittsburgh sleep quality index *Physical activity was categorized into the following levels: low: <600 (MET/min/week),medium: 600–2999 (MET/min/week) and high: ≥3000 (MET/min/week) Changes in calorie intake There was a significant reduction in calorie intake and a significant increase in protein intake in both groups. Moreover, no significant differences in calorie intake, protein, fat and carbohydrate intake were found between the intervention and control groups at the end of the study (results were shown elsewhere [22]). Changes in the MIND diet score As expected, the MIND group had a significant increase in dietary intake scores compared to the control group (Table 2). This increase was in the consumption of leafy green vegetables (p < 0.001), other vegetables (p = 0.003), berries (p < 0.001), nuts (p < 0.001), olive oil (p < 0.001), cheese (p < 0.001), whole grains (p = 0.017), non-fried fish (p < 0.001), and beans (p = 0.003). Additionally, the overall score in the MIND group showed a significant increase compared to the control group (p < 0.001). Table 2The differences in dietary intake of the MIND diet group compared to the control group during the studyVariablesMIND diet(n = 22)Control group(n = 22)Mean difference(95% CI) ≠P-valueGreen leafy vegetables (score)a Baseline0.25 (0.26)0.18 (0.29)−0.07 (−0.23, 0.10)0.001** Follow up0.82 (0.25)0.43 (0.18)< 0.001† P-value< 0.001*0.001*Other vegetables (score)b Baseline0.80 (0.37)0.66 (0.45)−0.14 (−0.39, 0.11)0.086** Follow up0.98 (0.11)0.61 (0.49)0.003† P-value0.029*0.665*Berries (score)c Baseline0.16 (0.36)0.14 (0.35)−0.02 (−0.24, 0.19)< 0.001** Follow up0.95 (0.21)0.20 (0.33)< 0.001† P-value< 0.001*0.329*Nuts (score) Baseline0.50 (0.27)0.43 (0.23)−0.07 (−0.22, 0.08)< 0.001** Follow up0.93 (0.18)0.52 (0.39)< 0.001† P-value< 0.001*0.162*Olive oil (score) Baseline00< 0.001** Follow up10< 0.001† P-value< 0.001*1*Butter, margarine (score) Baseline1.00 (0.00)1.00 (0.00)1** Follow up1.00 (0.00)1.00 (0.00)1† P-value1*1*Cheese (score) Baseline0.61 (0.21)0.73 (0.25)0.11 (−0.03, 0.26)< 0.001** Follow up0.98 (0.11)0.57 (0.18)< 0.001† P-value< 0.001*0.031*Whole grains (score) Baseline0.55 (0.41)0.48 (0.42)−0.07 (−0.32, 0.18)0.118** Follow up0.77 (0.25)0.50 (0.44)0.017† P-value0.021*0.803*Fish (not fried) (score) Baseline0.20 (0.30)0.18 (0.29)−0.02 (−0.20, 0.16)< 0.001** Follow up0.73 (0.30)0.27 (0.37)< 0.001† P-value< 0.001*0.162*Beans (score)d Baseline0.23 (0.25)0.23 (0.25)0.00 (−0.16,0.16)0.007** Follow up0.70 (0.25)0.45 (0.31)0.003† P-value< 0.001*< 0.001*Poultry (not fried) (score)e Baseline0.75 (0.34)0.59 (0.37)−0.16 (−0.37, 0.05)0.261** Follow up0.95 (0.15)0.91 (0.20)0.741† P-value0.009*< 0.001*Red meat and products (score) Baseline1.00 (0.00)1.00 (0.00)1** Follow up1.00 (0.00)1.00 (0.00)1† P-value1*1*Fast fried foods (score) Baseline1.00 (0.00)0.98 (0.11)−0.02 (−0.07, 0.02)1** Follow up1.00 (0.00)0.98 (0.11)1† P-value1*1*Pastries and sweets (score) Baseline0.95 (0.15)0.86 (0.32)−0.09 (−0.24, 0.06)0.328** Follow up0.93 (0.23)0.91 (0.29)0.582† P-value0.576*0.427*MIND diet score Baseline8.00 (1.20)7.41 (1.09)−0.59 (−1.29, 0.10)< 0.001** Follow up12.82 (0.59)8.39 (1.24)< 0.001† P-value< 0.001*< 0.001*aSpinach, lettuce, greens, collardsbCarrots, zucchini/summer squash/eggplant, green/red peppers, green beans, mushroom, garlic, onion, celery, cabbage, cucumbercMulberry, dried berries, blueberry, blackberry, strawberrydBeans, lentils, chickpease, soybeanseChicken, duck, turkey, quail. Data are shown as mean (standard deviation)≠Based on baseline comparisons*Based on paired sample t-test**Based on independent sample t-test†Based on linear regression after adjusted for baseline variables The differences in dietary intake of the MIND diet group compared to the control group during the study aSpinach, lettuce, greens, collards bCarrots, zucchini/summer squash/eggplant, green/red peppers, green beans, mushroom, garlic, onion, celery, cabbage, cucumber cMulberry, dried berries, blueberry, blackberry, strawberry dBeans, lentils, chickpease, soybeans eChicken, duck, turkey, quail. Data are shown as mean (standard deviation) ≠Based on baseline comparisons *Based on paired sample t-test **Based on independent sample t-test †Based on linear regression after adjusted for baseline variables Changes in anthropometric measurements The changes in anthropometric measures are shown in Table 3. At the end of the 3-month intervention, there was a significant reduction in WC, WHR, WHtR, and BRI in the MIND diet group compared to the control group (p < 0.05). The other indices including, BMI, BAI, LAP, VAI, CMI, and ABSI did not show any significant differences between the two groups (p >0.05). Detailed information on WC, WHR, and WHtR measurements is available in our previous study [22]. Table 3Comparison of the anthropometric measurements between groups at baseline and after 3 months of interventionVariablesMIND diet(n = 22)Control group(n = 22)Mean difference (95% CI)≠P-valueDifference in outcome measures between MIND diet and control groups aEffect size, β (95% CI)p-valueBRI Baseline6.50 (1.73)6.87 (0.93)0.37 (−0.48, 1.21)0.042**−0.27(−0.47, −0.06)0.011¥ End of trial6.01 (1.58)6.59 (0.87)0.009† P-value< 0.001*< 0.001* Effect sizeꭤ1.052.18BAI Baseline35.85 (3.55)36.42 (4.51)0.57 (−1.90, 3.04)0.680**0.12(−0.47, 0.71)0.688¥ End of trial35.64 (3.84)36.10 (4.44)0.688† P-value0.438*< 0.001* Effect size0.171.11LAP Baseline485.03 (220.59)482.50 (284.57)−2.54 (−157.45, 152.38)0.233£−30.48(−108.42, 47.46)0.433¥ End of trial376.85 (221.26)427.59 (231.18)0.188† P-value< 0.001€0.137 € Effect size0,890.33VAI Baseline575.49 (275.81)520.39 (352.45)−55.09 (−247.65, 137.47)0.321**−16.56(−94.27, 61.16)0.669¥ End of trial392.78 (186.53)403.63 (188.73)0.370† P-value< 0.001*0.043* Effect size1.050.46CMI Baseline3.20 (1.56)2.93 (1.97)−0.27 (−1.35, 0.81)0.314**−0.15(−0.60, 0.31)0.522¥ End of trial2.20 (1.07)2.31 (1.04)0.311† P-value< 0.001*0.058* Effect size1.040.43ABSI Baseline0.08 (0.004)0.08 (0.004)0.002 (−0.001, 0.004)0.108**−0.001 (−0.002, 0.00)0.057¥ End of trial0.08 (0.004)0.08 (0.004)0.124† P-value0.3100.085 Effect size0.220.39Data are shown as mean (standard deviation)ABSI a body shape index, BAI body adiposity index, BRI body roundness index, CMI cardiometabolic index, LAP lipid accumulation product index, VAI visceral adiposity indexa“Outcome measures” refers to the change in values of measures of interest between baseline andweek 12. β [difference in the mean outcomes measures between intervention groups (MIND dietgroup = 1 and control group = 0)]≠Based on baseline comparisons*Based on paired sample t-test**Based on independent sample t-test€Based on Wilcoxon test£Based on Mann-Whitney test†Based on linear regression after adjusted for baseline variables¥Based on linear regression after adjusted for baseline values, calorie intake, physical activity and weightꭤBased on Cohen’s effect size Comparison of the anthropometric measurements between groups at baseline and after 3 months of intervention Data are shown as mean (standard deviation) ABSI a body shape index, BAI body adiposity index, BRI body roundness index, CMI cardiometabolic index, LAP lipid accumulation product index, VAI visceral adiposity index a“Outcome measures” refers to the change in values of measures of interest between baseline andweek 12. β [difference in the mean outcomes measures between intervention groups (MIND dietgroup = 1 and control group = 0)] ≠Based on baseline comparisons *Based on paired sample t-test **Based on independent sample t-test €Based on Wilcoxon test £Based on Mann-Whitney test †Based on linear regression after adjusted for baseline variables ¥Based on linear regression after adjusted for baseline values, calorie intake, physical activity and weight ꭤBased on Cohen’s effect size Changes in cardiometabolic indices Changes in cardiometabolic indices are illustrated in Fig. 1. The independent-samples t-test shows a significant reduction in FBS, SBP, and DBP levels in the MIND diet group compared with the control group. For a detailed overview of the changes in glycemic status, lipid profile, and blood pressure, refer to Table 4. In the MIND group, significant reductions in FBS (p = 0.001), HbA1C (p < 0.001), insulin resistance (p = 0.005), TG (p = 0.002), TC (p = 0.003), LDL-c (p = 0.004), systolic blood pressure (SBP) (p < 0.001), and diastolic blood pressure (DBP) (p < 0.001) were observed after 3 months of intervention compared to baseline measurements. Additionally, insulin sensitivity (p = 0.004) and HDL-c (p = 0.036) increased significantly. These reductions were significant for FBS (p = 0.048), TC (p < 0.001), LDL-c (p = 0.002), SBP (p = 0.002), and DBP (p = 0.007) after adjustment for baseline variables compared to the control group. Changes in cardiometabolic indices (mean ± SD) in the MIND dietary pattern group (blue) and the control group (yellow) at baseline and after 12 weeks of intervention. *P < 0.05, obtained from the independent-samples t-test Table 4Comparison of the biochemical tests between groups at baseline and after 3 months of interventionVariablesMIND diet(n = 22)Control group(n = 22)Mean difference (95% CI) ≠P-valueDifference in outcome measures between MIND diet and control groups aEffect size, β (95% CI)P-valueFBS (mg/dl) Baseline146.77 (41.97)143.32 (41.67)−3.45 (−28.90, 21.99)0.046**−16.57 (−36.39, 3.26)0.099¥ End of trial117.45 (26.89)134.09 (57.40)0.048† P-value0.001*0.172* Effect sizeꭤ0.860.30HbA1C (%) Baseline7.64 (0.93)7.60 (1.24)−0.04 (−0.71, 0.62)0.450**−0.04 (−0.36, 0.28)0.788¥ End of trial7.02 (1.17)7.12 (0.95)0.453† P-value< 0.001*0.003* Effect size1.020.72Insulin (µU/ml) Baseline15.21 (4.76)16.09 (12.44)0.88 (−4.85, 6.61)0.557£0.95 (−2.71, 4.61)0.602¥ End of trial13.98 (8.91)15.02 (14.22)0.917† P-value0.205€0.256€ Effect size0.170.08QUICKI Baseline0.30 (0.01)0.31 (0.03)0.01 (−0.005, 0.02)0.256**0.008 (−0.01, 0.03)0.403¥ End of trial0.32 (0.03)0.32 (0.04)0.303† P-value0.004*0.057* Effect size0.700.43HOMA-IR Baseline4.98 (2.07)5.15 (4.64)0.17 (−2.01, 2.36)0.387**−0.96 (−2.82, 0.90)0.302¥ End of trial3.58 (2.13)4.55 (4.41)0.296† P-value0.005*0.464* Effect size0.670.16TG (mg/dl) Baseline196.64 (70.80)182.32 (98.92)−14.32 (−66.65, 38.02)0.202**−2.77 (−32.10, 26.57)0.849¥¥ End of trial161.14 (61.61)168.36 (84.40)0.252† P-value0.002*0.308* Effect size0.760.22TC (mg/dl) Baseline173.00 (43.48)178.95 (41.93)5.95 (−20.04, 31.94)0.050**−22.76 (−32.89, −12.63)< 0.001¥¥ End of trial147.41 (14.54)173.82 (27.41)< 0.001† P-value0.003*0.440* Effect size0.700.17HDL-c (mg/dl) Baseline42.09 (9.99)43.68 (7.38)1.59 (−3.75, 6.94)0.788**0.02 (−4.36, 4.41)0.992¥¥ End of trial46.50 (5.32)47.36 (8.20)0.841† P-value0.036*0.058* Effect size0.480.43LDL-c (mg/dl) Baseline91.58 (33.11)98.81 (31.24)7.23 (−12.36, 26.81)0.109**−21.11 (−32.10, − 10.12)< 0.001¥¥ End of trial70.46 (19.64)92.78 (23.85)0.002† P-value0.004*0.358* Effect size0.680.20SBP (mmHg) Baseline131.82 (12.82)133.50 (13.07)1.68 (−6.20, 9.56)0.008**−6.96 (−12.05, −1.88)0.009¥¥ End of trial119.95 (9.41)128.86 (13.65)0.002† P-value< 0.001*0.003* Effect size1.140.73DBP (mmHg) Baseline87.45 (5.21)86.68 (7.76)0.95 (−5.04, 6.95)0.016**−6.95 (−10.98, −2.92)0.001¥¥ End of trial82.45 (2.70)84.45 (6.82)0.007† P-value< 0.001*0.002* Effect size1.190.73Data are shown as mean (standard deviation)DBP diastolic blood pressure, FBS fasting blood sugar, HbA1C hemoglobin A1C, HDL high density lipoprotein, LDL low density lipoprotein, SBP systolic blood pressure, TC total cholesterol, TG triglyceride≠Based on baseline comparisonsa“Outcome measures” refers to the change in values of measures of interest between baseline andweek 12. β [difference in the mean outcomes measures between intervention groups (MIND dietgroup = 1 and control group = 0)]*Based on paired sample t-test**Based on independent sample t-test€Based on Wilcoxon test£Based on Mann-Whitney test†Based on linear regression after adjusted for baseline variables¥Based on linear regression after adjusted for baseline values, age, physical activity, weight reduction, calorie intake, menopausal status, and duration of diabetes¥¥Based on linear regression after adjusted for baseline values, age, physical activity, weight reduction, calorie intake, menopausal status, medication use, and duration of diabetesꭤBased on Cohen’s effect size Comparison of the biochemical tests between groups at baseline and after 3 months of intervention Data are shown as mean (standard deviation) DBP diastolic blood pressure, FBS fasting blood sugar, HbA1C hemoglobin A1C, HDL high density lipoprotein, LDL low density lipoprotein, SBP systolic blood pressure, TC total cholesterol, TG triglyceride ≠Based on baseline comparisons a“Outcome measures” refers to the change in values of measures of interest between baseline andweek 12. β [difference in the mean outcomes measures between intervention groups (MIND dietgroup = 1 and control group = 0)] *Based on paired sample t-test **Based on independent sample t-test €Based on Wilcoxon test £Based on Mann-Whitney test †Based on linear regression after adjusted for baseline variables ¥Based on linear regression after adjusted for baseline values, age, physical activity, weight reduction, calorie intake, menopausal status, and duration of diabetes ¥¥Based on linear regression after adjusted for baseline values, age, physical activity, weight reduction, calorie intake, menopausal status, medication use, and duration of diabetes ꭤBased on Cohen’s effect size Discussion To the best of our knowledge, this study was the first RCT that assessed the effect of adherence to the MIND diet on cardiometabolic risk factors in women with diabetes and insomnia. Our results showed that there were no significant differences between the two groups at baseline. After three months of intervention, as expected, the consumption scores of vegetables, berries, nuts, olive oil, cheese, whole grains, fish, and beans increased significantly in the MIND diet group compared to the control group. This led to a significant improvement in the overall scores achieved by adherence to the MIND diet in the intervention group compared to the control group. This study used a combination of traditional and new anthropometric indices to assess obesity status. Indices such as BMI as a measure of general obesity have some limitations, as adipose tissue cannot be distinguished from muscle tissue and it is only a measure of body weight [36]. Other traditional anthropometric indices such as WC, WHR, and WHtR were used to assess central obesity [37]. In our study, WC, WHR, and WHtR decreased significantly in the MIND diet group compared to the control group after 3 months of the intervention. Although a significant reduction in WC was observed in these individuals, the values did not reach normal levels. This outcome may be attributed to factors such as the sample size, the duration of the intervention, and the exclusion of dairy intake as an important source of calcium, casein, and conjugated linoleic acid in this dietary pattern [38]. Moreover, novel anthropometric indices were calculated in this study. Studies have shown a relationship between new anthropometric indices and cardiovascular risk factors [29–31, 39]. The BRI is an index of body roundness and fat distribution in the body [27]. The BAI indicates the percentage of body fat [28]. The VAI, LAP, and CMI indices distinguish visceral fat from subcutaneous fat [29–31], and the ABSI is associated with abdominal fat [32]. In this study, the BRI decreased at the end of the intervention compared to the control group. Given the beta coefficients for WC (1.73), WHR (0.02), WHtR (0.11), and BRI (0.27), the effect size appears to be modest, suggesting that longer intervention periods may be required to achieve more substantial changes. These findings suggest that while the MIND diet may positively influence central and overall adiposity, more substantial clinical improvements may require longer intervention durations or additional lifestyle modifications. Similar to our findings, a cross-sectional study found a significant inverse association between Healthy Eating Index-2015 (HEI-2015) and BRI in patients with diabetes after adjusting for confounding variables [40]. However, in the study by Jalalzadeh et al., no association was found between dietary phytochemical index (DPI) and ABSI, BRI, and abdominal volume index (AVI) in diabetic patients [41]. Another cross-sectional study found no significant association between the Lifelines Diet Score (LLDS) and new anthropometric indices [42]. Moreover, interventions with polyphenol-rich Mediterranean diets have significantly reduced in visceral adipose tissue (VAT) compared with traditional Mediterranean diets [43]. These findings are consistent with other research, such as a study in a multiethnic population that showed a significant inverse association between HEI-2010 scores and VAT, further emphasizing the importance of diet quality in controlling visceral adiposity [44]. The discrepancies in the results of our study could be due to the different ethnicity of the participants, the design of the study, the specific characteristics of the dietary pattern, and the confounding variables adjusted for in the analysis. Adipose tissue dysregulation, characterized by an imbalance of adiponectin and leptin, contributes to micro- and macrovascular complications by promoting dyslipidemia, inflammation, and atherosclerosis [45]. Previous studies have demonstrated that green leafy vegetables, berries, and legumes, key components of the MIND diet, can influence satiety-related hormones (such as CCK, GLP-1, and PYY), modulate the gut microbiome [46, 47], and contribute to reduced inflammation and improved metabolic regulation [48]. These components may also affect fat and carbohydrate digestion, modulate adipocyte function, and enhance gut microbiome balance [48]. Furthermore, the MIND diet encourages replacing saturated fats with MUFAs and emphasizes the consumption of olive oil, which has been associated with shifting fat storage away from visceral depots [49] and enhancing gut-brain satiety signals via oleoylethanolamide [50]. This study showed that a 3-month intervention with the MIND diet resulted in significant reductions in FBS, TC, LDL-c, and blood pressure compared to the control group, after adjusted for baseline variables. Considering the beta coefficients for TC (22.76), LDL-c (21.11), SBP (6.96), and DBP (6.95), the magnitude of these associations suggests relatively small but potentially meaningful changes, indicating that a longer intervention duration or combined dietary and lifestyle strategies may be necessary to achieve more pronounced cardiometabolic effects. Similar to our findings, a cross-sectional study found significant inverse associations between adherence to the MIND diet and TG, FBS, and blood pressure in healthy adults [18]. Another study on obese individuals showed a significant association of the MIND diet with only insulin sensitivity but not other cardiometabolic markers [19]. Similarly, a study by Zare et al., on elderly patients with DM, revealed only a significant association between following the MIND diet and blood pressure, but not with other lipid markers or blood glucose levels [51]. Another cross-sectional study showed a significant negative association between the adapted HEI scores and FBS and HbA1C in men and women with type 2 DM [52]. In contrast, results of a clinical trial by Yau et al., reported significant reductions in TC, LDL-c, and glucose after a 4-week MIND diet intervention in elderly hypertensive patients [20]. In addition, intervention with a 12-week Mediterranean diet showed improvements in glucose, TG, HDL-c, and blood pressure [53]. A meta-analysis of studies on the DASH diet showed a significant decrease in blood pressure, TC, and LDL-c, but not in glucose or insulin-related markers [54]. Most studies have demonstrated the beneficial impacts of a healthy diet on cardiometabolic markers, which confirms the findings of our study. However, the lack of significant differences in indices of insulin resistance and sensitivity, HbA1C, HDL-c, and TG between the intervention and control groups could be attributed to limitations related to sample size and intervention duration. Studies have shown that flavonols, which are abundant in vegetables and certain berries, significantly reduce TC, LDL-c, TG, glucose, SBP, and DBP. They also increase HDL-c [55]. Products containing anthocyanins and ellagitannins (berries and nuts) could decrease TC levels more than pomegranates and grapes. The consumption of anthocyanin-rich foods such as berries, red grapes, or wine also led to a reduction in blood pressure, while products containing ellagitannin - especially nuts- led to a significant decrease in WC, LDL-c, TG, and glucose. In addition, the consumption of nuts was associated with a substantial increase in HDL-c levels [56]. Flavonoids play an essential role in cardiometabolic health as they improve oxidative stress, insulin sensitivity, glucose tolerance, inflammatory status, lipid metabolism, and adipocyte differentiation [57–60]. The Mediterranean diet, a component of the MIND diet, also emphasizes whole grains, healthy fats, natural antioxidants, and fiber. Consumption of these foods may reduce in activation of the innate immune system by decreasing the production of pro-inflammatory cytokines and increasing anti-inflammatory cytokines [61]. This may lead to an anti-inflammatory environment that may improve insulin sensitivity in peripheral tissues and endothelial function at the vascular level [61]. These changes serve as a protective mechanism against the development of metabolic syndrome, type 2 diabetes, and atherosclerosis [61]. Although the observed effect sizes were modest, they may have meaningful clinical implications for reducing cardiovascular risk factors in this vulnerable population. Improvements in TC, LDL-c, SBP, and DBP, along with reductions in WC, WHR, WHtR, and BRI, collectively contribute to lowering the risk of cardiometabolic diseases. If sustained over longer periods, these changes could translate into significant health benefits, including a reduced incidence of cardiovascular events and mortality. Our study has several key strengths. First, it is the first to examine the effects of the MIND diet on cardiometabolic risk factors in diabetic patients with insomnia. Second, we included novel anthropometric markers in our study as they are more closely related to CVD. Third, we considered several potentially confounding variables in the analysis. However, some limitations include focusing only on female participants, the relatively small sample size and study duration, the failure to analyze body composition, and reliance on self-reported adherence introduces potential bias. Moreover, due to financial and access limitations, measurements of key hormones (ghrelin, leptin, CCK, PYY, GIP, GLP-1) and assessments using body composition analyzers could not be performed. Given that this study was conducted exclusively among women with diabetes and insomnia, the findings may not be directly generalizable to men or other populations. Conclusion A 3-month intervention with the MIND diet demonstrates encouraging improvements in several cardiometabolic and anthropometric markers in women with type 2 DM and insomnia. These initial findings suggest a safe and practical dietary strategy to decrease CVD risk in these vulnerable people; however, larger, longer-term trials involving more diverse populations are essential to confirm and expand these results. Moreover, the body composition analysis, including segmental assessment of fat and muscle and investigation of the role of gut microbiota, will be crucial to clarify the underlying mechanisms and confirm the efficacy of the MIND diet. Supplementary Information Supplementary Material 1. Acknowledgements The authors would like to sincerely thank the participants for their commitment and cooperation throughout the study. This trial was financially supported by Kermanshah University of Medical Sciences, Kermanshah, Iran (Grant numbers: 4020342). Authors’ contributions M.G.: Conceptualization, Data Curation, Methodology, Formal Analysis, Writing. V.E.A.: Review and editing. Y.S.: Data Curation, Methodology. L.S.: Acquisition of Data. M.S.: Conceptualization, Supervising, Review and editing. S.M.N.: Conceptualization, Supervising, Review and editing. Funding This trial was financially supported by Kermanshah University of Medical Sciences, Kermanshah, Iran (Grant numbers: 4020342). Data availability The data associated with the paper are not publicly available but are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study received ethical approval from the Ethics Committee at Kermanshah University of Medical Sciences (IR.KUMS.REC.1402.170). Following the ethical principles outlined in the Declaration of Helsinki by the World Medical Association, participants received detailed information about the objectives and procedures of the study, after which they provided their consent by signing a formal agreement. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Seyed Mostafa Nachvak, Email: smnachvak@hotmail.com. Mehnoosh Samadi, Email: mehnoosh_samadi@yahoo.com. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The data associated with the paper are not publicly available but are available from the corresponding author on reasonable request.